Your new post is loading...
Type 2 diabetes is on the rise in the U.S.--and so is TV adspending for drugs to treat the condition. New medicines, along with increased marketing budgets on older meds, more than doubled diabetes category spending on TV advertising in 2015 to $468 million, up from $194 million in 2014, according to data collected by real-time TV tracker iSpot.tv.
The four new diabetes drug entrants to TV advertising last year were Sanofi's ($SNY) Toujeo, Boehringer Ingelheim and Eli Lilly's ($LLY) Jardiance, Eli Lilly's Trulicity, and GlaxoSmithKline's ($GSK) Tanzeum.
However, it was Johnson & Johnson's Invokana, already on the airwaves, that made the biggest splash, spending $101.2 million on TV ads in 2015, up from $35.2 million in 2014. iSpot noted that just one Invokana ad, "You're Not Alone," accounted for an estimated $75 million additional spending, or 16% of the category total for the year.
Was all the TV ad spending for Invoking worth it? Find out here: http://bit.ly/1Kbh0NV